Key result
Pilsicainide linked to markedly reduced atrial flutter in a patient with ARVD.
Case Report (n=1)
This case highlights the potential overlap of post-inflammatory or primary endomyocardial fibroelastic changes with ARVD, including left ventricular involvement.
Answers are grounded in this paper and cite their sources.
Single-case pilsicainide response in ARVD flutter warrants caution; leaves open generalizability and need for controlled trials.
A 57-year-old male who had arrhythmogenic right ventricular dysplasia (ARVD) with recurrent atrial flutter (AF) is reported. The patient had more frequent episodes of AF than of ventricular arrhythmias. Magnetic resonance imaging, echocardiography and right ventriculography revealed dilatation of the right ventricle and endomyocardial biopsy specimens from the right ventricle showed findings which were compatible with ARVD. The left ventricular specimen, however, also revealed a loss of myocytes and interstitial fibroelastic changes. The present case demonstrates an overlap of post-inflammatory or primary endomyocardial fibroelastic changes with ARVD.
No takes yet. Share an insight, caveat, or question.
Nakazato et al. (1994) conducted a case report in Arrhythmogenic right ventricular dysplasia (ARVD) with recurrent atrial flutter (n=1). Pilsicainide was evaluated on Incidence of atrial flutter. Administration of pilsicainide (/day) markedly decreased the incidence of atrial flutter in a 57-year-old male with arrhythmogenic right ventricular dysplasia.
Synapse has enriched 10 related papers. Consider them for comparative context: